Partner Headlines - MDVN

  1. Four Hot Stocks You'll Want To Keep On Your Radar

    IBD
  2. Nasdaq, S&P 500 Hang Tough; Avago, Akorn Big Earnings Winners

    IBD
  3. Medivation Tops Q4 Views On Strong Xtandi Results

    IBD
  4. Stocks Mixed; United Therapeutics Jumps To New High

    IBD
  5. Market Edges Higher, Unfazed By Weak HP Results

    IBD
  6. Market's Resilience Is Noteworthy; More Breakouts Emerge

    IBD
  7. Earnings Scheduled For February 25, 2015

    Benzinga
  8. Stocks Show Small Losses; Merger Talk Lifts Discovery

    IBD
  9. Stocks Quietly Lower; Domino's, Medivation Break Out

    IBD
  10. Wedbush Weighs in on Medivation Following Phase II TERRAIN Study ...

    GuruFocus
  11. Valeant Agrees To Buy Dendreon's Provenge

    IBD
  12. Weekly CEO Sells Highlight: QAD Inc, Orbitz Worldwide Inc, Constellation ...

    GuruFocus
  13. Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically ...

    GuruFocus
  14. J&J Earnings Beat, But Sales, Guidance Miss Estimates

    IBD
  15. Eli Lilly Has 'Turned The Corner,' Upgraded

    IBD
  16. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  17. Barclays Analyst Sees Biotech FY15 EPS Growth Outstripping Market

    Benzinga
  18. William Blair's Top BioPharmaceutical Stock Picks for Q1 2015

    GuruFocus
  19. Newly Profitable Medivation Riding High On Drug Sales

    IBD
  20. Chip Stocks, Biotechs Lead Another Nasdaq Rally

    IBD
  21. Major Upgrades And Downgrades In Friday's Market Action

    Benzinga
  22. Medivation Hits High After Q3 Earnings Beat

    IBD
  23. Medivation Hits High After Q3 Earnings Beat

    IBD
  24. Medivation and Astellas Announce Phase 3 Study of Enzalutamide ...

    GuruFocus
  25. J&J Earnings Beat; Olysio Chatter Hits Gilead

    IBD
  26. Consider Medivation for Your Portfolio

    FoxBusiness
  27. Benzinga's Top Downgrades

    Benzinga
  28. Goldman Sachs Downgrades Medivation To Neutral, Shares Drop

    Benzinga
  29. These 3 Biotech Stocks Just Hit New Highs

    Benzinga
  30. Fast Money Halftime Report Final Trade From September 12

    Benzinga
  31. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD
  32. Stifel Raises Medivation Inc Price Target

    Benzinga
  33. Stocks Hitting 52-Week Highs

    Benzinga
  34. A Few Reasons Why Investors Should Consider Dendreon for Their ...

    GuruFocus
  35. Medivation Cancer Drug Fuels Beat, Swings To Profit

    IBD
  36. Benzinga's Volume Movers

    Benzinga
  37. Medivation Announces Change in Executive Management Team; Dawn ...

    Benzinga
  38. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  39. Aegis Capital Believes Seragon Deal Underscores Value In Medivation

    Benzinga
  40. UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer ...

    Benzinga
  41. Benzinga's Top Upgrades

    Benzinga
  42. US Stock Futures Flat Ahead Of International Trade Data

    Benzinga
  43. UPDATE: Canaccord Genuity Initiates Coverage on Medivation as ...

    Benzinga
  44. Morning Market Movers

    Benzinga
  45. Stocks To Watch For April 1, 2014

    Benzinga
  46. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, ...

    Benzinga
  47. UPDATE: Astellas Announces Marketing Approval in Japan for XTANDI® ...

    Benzinga
  48. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  49. Market Wrap For February 28: Markets Unable To Hold On To Gains

    Benzinga
  50. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  51. Benzinga's Top #PreMarket Losers

    Benzinga
  52. 2 Deaths, 25% Plunge -- And Still A Big Upside

    YCharts
  53. Mid-Afternoon Market Update: Fed Will Continue the Taper in February

    Benzinga
  54. Mid-Day Market Update: Yahoo! Slips After Q4 Results; RF Micro ...

    Benzinga
  55. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  56. Mid-Morning Market Update: Markets Open Lower; Dow Chemical Posts ...

    Benzinga
  57. Stocks Hitting 52-Week Highs

    Benzinga
  58. Benzinga's Top #PreMarket Gainers

    Benzinga
  59. Medivation and Astellas Announce Final Results From the Phase ...

    Benzinga
  60. UPDATE: Aegis Capital Reiterates on Medivation Following In-Line ...

    Benzinga
  61. Medivation, Astellas Announce Phase 3 PREVAIL Trial of Enzalutamide ...

    Benzinga
  62. Uh Oh: Is This Cancer Highflyer In Your Account?

    YCharts
  63. Worse-Than-Expected Xtandi Sales Hitting Shares of Medivation; ...

    Benzinga
  64. Medivation Elects Kathryn Falberg to Board of Directors

    Benzinga
  65. Medivation Bulls Load Up on Call Options

    SchaeffersResearch
  66. Aegis Capital Corp. Reiterates Buy Rating, $100 PT on Medivation

    Benzinga
  67. Medivation, Inc. (MDVN) President and CEO David Hung sells 1 ...

    GuruFocus
  68. Benzinga's Top Initiations

    Benzinga
  69. Celgene, Regeneron Pharmaceutical Lead Biomed Group

    IBD
  70. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  71. UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Medivation

    Benzinga
  72. Medivation Effects 2-for-1 Stock Split

    Benzinga
  73. Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)

    Benzinga
  74. US FDA Approves XTANDI for Patients With Metastatic Castration-Resistant ...

    Benzinga
  75. Medivation Reports 2-for-1 Forward Split of Common Stock

    Benzinga
  76. Andreas Halvorsen Buys 2 Million Shares of Medivation

    GuruFocus
  77. Medivation Inc. (MDVN) President and CEO David Hung sells 25, ...

    GuruFocus
  78. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  79. Stocks Hitting 52-Week Highs

    Benzinga
  80. Health Care Sector Wrap

    FoxBusiness
  81. Four Winning Trades Based on Analyst Calls

    Benzinga
  82. Medivation Bull Looks to Cash In on Continued Rally

    SchaeffersResearch
  83. Analyst Upgrades: MDVN, SCHN, and STI

    SchaeffersResearch
  84. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  85. Citigroup Reiterates Buy Rating, $129 PT for Medivation

    Benzinga
  86. Medivation and Astellas Announce Enzalutamide Data

    Benzinga
  87. Crazy Action in Medivation After Negative StreetSweeper Post

    Benzinga
  88. Global Fears and Small Caps: How Much of an Impact?

    Benzinga
  89. Social Media Outlook for Tuesday 15 (DKS, MDVN, BBY, ACOM)

    Benzinga
  90. GlaxoSmithKline, Vertex Point To Biotech Strength

    IBD
  91. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  92. Will Johnson & Johnson Cure Cancer?

    Benzinga
  93. Options Players Show a Preference for Medivation Puts

    SchaeffersResearch
  94. Notable Put Options Activity in Medivation

    Benzinga
  95. Weekly CFO Sells Highlight: SLCA, UNH, LVS, RATE, MDVN, YUM, ...

    GuruFocus
  96. Medivation's Stellar Technical Performance Entices Option Bulls

    SchaeffersResearch
  97. Benzinga's M&A Chatter for Wednesday February 1, 2012

    Benzinga
  98. Medivation Soars on Phase III Trial Data; Stock Up 21%

    Benzinga
  99. Jefferies Raises PT on Medivation to $95

    Benzinga
  100. Wedbush Raises PT on Medivation to $81

    Benzinga
Trading Center